Milestone Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Joining us today for the Milestone Pharmaceuticals presentation at the 43rd Annual TD Cowen Healthcare Conference. I'm covering analyst, Ritu Baral. And here with us for Milestone is President and CEO, Joe Oliveto and Joe will be taking us through the etripamil PSVT program and the recent progress on getting it under review. Joe?
I think [I'm miked up here, Ritu]. So, thanks again, Ritu, and thanks to all the colleagues at Cowen for having us here today and appreciate everyone in the audience for taking the time out as well as those that are online to hear the milestone story, and I will be making forward-looking statements. So, we'll direct you to our SEC filings for a full list of disclosures.
We just announced yesterday some recent news on both our PSVT program and our clinical trials in PSVT as well as regulatory guidance. Really excited to share that today from the podium. First, that we had our pre-NDA meeting with the FDA, where we proposed the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |